Britain's cost effectiveness watchdog NICE has recommended that Pfizer's inhaled insulin product Exubera should not be prescribed on the NHS, the drug maker said today.
Pfizer said the preliminary opinion from the National Institute for Health and Clinical Excellence (NICE) was "perverse and short-sighted".
Way to go guys. Insults always work.
More here.
No comments:
Post a Comment